CD5 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide is an immunomodulatory drug that indirectly influences CD5 signaling by affecting the tumor microenvironment. It exerts anti-inflammatory and antiangiogenic effects, impacting immune cell function. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a protein kinase C (PKC) inhibitor that indirectly modulates CD5 signaling by interfering with downstream intracellular pathways. By inhibiting PKC, Sotrastaurin disrupts the activation of signaling cascades involved in T-cell activation, potentially affecting CD5-mediated responses. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Cal-101, also known as Idelalisib, is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly influences CD5 signaling through the PI3K/AKT pathway. By inhibiting PI3K, Cal-101 disrupts downstream signaling events that contribute to T-cell activation and survival. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that indirectly influences CD5 signaling by disrupting B-cell receptor (BCR) signaling. By inhibiting BTK, Ibrutinib interferes with downstream pathways essential for B-cell activation and survival. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
R788 is a spleen tyrosine kinase (SYK) inhibitor that indirectly modulates CD5 signaling by interfering with downstream pathways. By inhibiting SYK, Fostamatinib disrupts signaling events crucial for B-cell activation, including those associated with CD5-mediated responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, also known as Sirolimus, indirectly influences CD5 signaling through its effects on mammalian target of rapamycin (mTOR) pathways. By inhibiting mTOR, Rapamycin disrupts downstream signaling events crucial for T-cell activation and survival, impacting CD5-mediated responses. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a dual BCR-ABL and Src family kinase inhibitor that indirectly modulates CD5 signaling by targeting Src kinases. By inhibiting Src kinases, Dasatinib interferes with downstream intracellular pathways essential for B-cell activation, including those associated with CD5-mediated responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK)1/2 inhibitor that indirectly influences CD5 signaling by interfering with JAK/signal transducer and activator of transcription (STAT) pathways. By inhibiting JAK1/2, Ruxolitinib disrupts downstream intracellular signaling events crucial for T-cell activation. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that indirectly influences CD5 signaling by disrupting B-cell receptor (BCR) signaling. By inhibiting BTK, Acalabrutinib interferes with downstream pathways essential for B-cell activation and survival, including those connected to CD5-mediated responses. | ||||||